| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | TPS2 |
| Uniprot No | P20231 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 31-275aa |
| 氨基酸序列 | IVGGQEAPRSKWPWQVSLRVHGPYWMHFCGGSLIHPQWVLTAAHCVGPDVKDLAALRVQLREQHLYYQDQLLPVSRIIVHPQFYTAQIGADIALLELEEPVNVSSHVHTVTLPPASETFPPGMPCWVTGWGDVDNDERLPPPFPLKQVKVPIMENHICDAKYHLGAYTGDDVRIVRDDMLCAGNTRRDSCQGDSGGPLVCKVNGTWLQAGVVSWGEGCAQPNRPGIYTRVTYYLDWIHHYVPKKP |
| 预测分子量 | 31.4 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于TPS2重组蛋白的3篇示例参考文献(注：文献为示例性质，非真实存在)：
1. **《Functional characterization of recombinant TPS2 in Saccharomyces cerevisiae》**
- Author: Zhang, L. et al.
- 摘要：研究通过在大肠杆菌中重组表达酵母TPS2蛋白，验证其海藻糖合成酶活性，并证明其在提高酵母耐干燥胁迫中的作用。
2. **《Optimization of TPS2 recombinant protein production in Pichia pastoris》**
- Author: Kim, S. & Park, J.
- 摘要：利用毕赤酵母系统高效表达TPS2重组蛋白，优化发酵条件获得高纯度产物，为工业化应用提供技术基础。
3. **《Structural analysis of TPS2 reveals key domains for thermotolerance》**
- Author: Müller, R. et al.
- 摘要：通过X射线晶体学解析重组TPS2蛋白的三维结构，阐明其催化活性中心及耐热性相关结构域，指导酶工程改造。
4. **《Heterologous expression of plant TPS2 enhances abiotic stress resistance in transgenic Arabidopsis》**
- Author: Chen, Y. et al.
- 摘要：将拟南芥TPS2基因在昆虫细胞中重组表达，证明其蛋白通过海藻糖积累提高植物对盐和干旱胁迫的抗性。
(提示：实际文献需通过数据库如PubMed/Google Scholar检索确认。)
**Background of TPS2 Recombinant Protein**
TPS2 (Thrombopoietin Mimetic Peptide 2) recombinant protein is a biologically engineered molecule designed to mimic the activity of thrombopoietin (TPO), a key cytokine regulating platelet production. Thrombopoietin naturally binds to the c-MPL receptor on megakaryocytes, stimulating their proliferation and differentiation into platelets. TPS2 was developed to address limitations of native TPO, such as immunogenicity and instability, while retaining its therapeutic potential.
Constructed using recombinant DNA technology, TPS2 typically combines a TPO receptor-binding peptide sequence with stabilizing structural elements, such as Fc regions or polyethylene glycol (PEG) chains, to enhance pharmacokinetics. This engineering improves bioavailability and reduces rapid clearance in vivo. The protein is commonly expressed in mammalian cell systems (e.g., CHO cells) to ensure proper post-translational modifications and functionality.
Clinically, TPS2 has been explored for treating thrombocytopenia, particularly in patients undergoing chemotherapy or with immune-mediated platelet disorders. Its ability to stimulate platelet production without triggering neutralizing antibodies (a drawback of early TPO analogs like romiplostim) positions it as a safer alternative. Additionally, research extends to hematopoietic recovery post-bone marrow transplantation and as an adjunct in bleeding disorders.
Preclinical studies highlight its dose-dependent efficacy and tolerability, though long-term safety profiles remain under investigation. TPS2 exemplifies advancements in protein engineering to optimize therapeutic proteins for enhanced stability, reduced immunogenicity, and targeted biological effects. Its development underscores the intersection of molecular biology and clinical needs in hematology.
×
